 |
인쇄하기
취소
|
Green Cross to market medicine for irritable bowel syndrome, Algiron
Green Cross Corporation entered into an exclusive agreement with Boehringer Ingelheim Korea over Algiron (cimetropium bromide).
Under the agreement, GCC will market the new antimuscarinic compound in Korea on an exclusive basis.
Studies have shown that Algiron is effective in relieving pain in patients with irritable bowel syndrome (IBS). IBS is common in the general population and has si...
Under the agreement, GCC will market the new antimuscarinic compound in Korea on an exclusive basis.
Studies have shown that Algiron is effective in relieving pain in patients with irritable bowel syndrome (IBS). IBS is common in the general population and has si...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.